ATE501267T1 - Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs - Google Patents

Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs

Info

Publication number
ATE501267T1
ATE501267T1 AT06717624T AT06717624T ATE501267T1 AT E501267 T1 ATE501267 T1 AT E501267T1 AT 06717624 T AT06717624 T AT 06717624T AT 06717624 T AT06717624 T AT 06717624T AT E501267 T1 ATE501267 T1 AT E501267T1
Authority
AT
Austria
Prior art keywords
biomarker
prostate cancer
isoform
useful
apolipoprotein
Prior art date
Application number
AT06717624T
Other languages
English (en)
Inventor
John Semmes
Gunjan Malik
Michael Ward
Original Assignee
Eastern Virginia Med School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School filed Critical Eastern Virginia Med School
Application granted granted Critical
Publication of ATE501267T1 publication Critical patent/ATE501267T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
AT06717624T 2005-01-06 2006-01-06 Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs ATE501267T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64233205P 2005-01-06 2005-01-06
PCT/US2006/000450 WO2006074360A2 (en) 2005-01-06 2006-01-06 Apolipoprotein a-ii isoform as a biomarker for prostate cancer

Publications (1)

Publication Number Publication Date
ATE501267T1 true ATE501267T1 (de) 2011-03-15

Family

ID=36648206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717624T ATE501267T1 (de) 2005-01-06 2006-01-06 Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs

Country Status (8)

Country Link
US (1) US7811772B2 (de)
EP (1) EP1838867B1 (de)
JP (1) JP2008527351A (de)
AT (1) ATE501267T1 (de)
AU (1) AU2006203948A1 (de)
CA (1) CA2593184A1 (de)
DE (1) DE602006020544D1 (de)
WO (1) WO2006074360A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
AU2008285557B2 (en) 2007-07-19 2014-07-03 Biomerieux Method for the assay of liver fatty acid-binding protein, ACE and CA19-9 for the in vitro diagnosis of colorectal cancer
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
CN101999077A (zh) * 2008-02-07 2011-03-30 哈达斯特医学服务与开发有限公司 受试者中癌状态的免疫检测
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
JP2015518152A (ja) * 2012-04-27 2015-06-25 イースタン バージニア メディカル スクール 前立腺がんの検出用バイオマーカーの定量
EP2844770A4 (de) * 2012-05-04 2016-08-10 Nuclea Biotechnologies Inc Mrm-ms-signaturtest
JP2014021083A (ja) * 2012-07-24 2014-02-03 Hitachi High-Technologies Corp 質量分析方法及び質量分析システム
AU2014228009A1 (en) * 2013-03-15 2015-10-08 Sera Prognostics, Inc. Biomarkers and methods for predicting preeclampsia
ES2836127T3 (es) 2013-03-15 2021-06-24 Sera Prognostics Inc Biomarcadores y métodos para predecir el parto prematuro
BR112016007037B1 (pt) * 2013-10-01 2023-12-26 National Cancer Center Método para detectar câncer pancreático
WO2016054031A1 (en) 2014-10-02 2016-04-07 Biodesix, Inc. Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
CN104503429B (zh) * 2014-11-26 2017-06-06 中车青岛四方机车车辆股份有限公司 轨道交通车辆静态试验数据自动化处理方法及装置
JP6677655B2 (ja) * 2015-01-26 2020-04-08 東レ株式会社 胆道癌の検出方法及び胆道癌検出用キット
CN107407681B (zh) * 2015-03-02 2020-06-30 东丽株式会社 胰功能异常的检测方法和检测用试剂盒
RU2724013C2 (ru) 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
WO2019036032A1 (en) 2017-08-18 2019-02-21 Sera Prognostics, Inc PREGNANCY CLOCK PROTEINS FOR PREDICTING THE DATE AND MOMENT OF BIRTH
WO2019200410A1 (en) 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5512657A (en) 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
DE4023945A1 (de) 1990-07-27 1992-01-30 Progen Biotechnik Gmbh Verfahren zur reinigung von cytokeratin 20 und dessen verwendung zur erzeugung von antikoerpern
JPH07507394A (ja) 1992-05-29 1995-08-10 ザ ロックフェラー ユニバーシティ 質量スペクトロメータを用いてペプチドの配列決定を行う為の方法及び物質
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6020208A (en) 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
PT700521E (pt) 1993-05-28 2003-10-31 Baylor College Medicine Metodo e espectrometro de massa para dessorcao e ionizacao de analitos
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1068356B8 (de) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Adressierbare protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
GB9821170D0 (en) 1998-09-30 1998-11-25 Univ Ulster Marker
AU1915000A (en) 1998-11-17 2000-06-05 University Of Maryland Methods for identifying and classifying organisms by mass spectrometry and database searching
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
DE60045816D1 (de) 1999-04-27 2011-05-19 Bio Rad Laboratories Probenhalter für ein gasphaseionenspektrometer
CN1169188C (zh) 1999-04-29 2004-09-29 赛弗根生物系统股份有限公司 具有憎水覆层的气相质谱仪样品支架
US6482599B1 (en) 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
ATE356357T1 (de) 2000-03-20 2007-03-15 Eastern Virginia Med School Prostatakrebs-marker
WO2002006832A1 (fr) * 2000-07-13 2002-01-24 International Reagents Corporation Moyen d'examen pour la nephropathie
WO2002006829A2 (en) 2000-07-18 2002-01-24 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
WO2003031031A1 (en) 2000-11-16 2003-04-17 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
EP1446044A4 (de) 2001-02-09 2007-08-08 Pintex Pharmaceuticals Inc Pin1 als marker für prostatakrebs
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7541003B2 (en) 2001-07-17 2009-06-02 Bio-Rad Laboratories, Inc. Latex based adsorbent chip
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20040018519A1 (en) 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US20030207462A1 (en) 2002-01-25 2003-11-06 Ciphergen Biosystems, Inc. Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
US7704700B2 (en) 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
WO2003091695A2 (en) 2002-04-26 2003-11-06 The Johns Hopkins University Identification of biomarkers for detecting prostate cancer
JP2005526972A (ja) 2002-05-02 2005-09-08 シファーゲン バイオシステムズ， インコーポレイテッド 多糖系ヒドロゲルをコーティングした表面を有するバイオチップ
JP2006509186A (ja) 2002-05-10 2006-03-16 イースタン バージニア メディカル スクール 前立腺癌バイオマーカー

Also Published As

Publication number Publication date
AU2006203948A1 (en) 2006-07-13
EP1838867B1 (de) 2011-03-09
DE602006020544D1 (de) 2011-04-21
US7811772B2 (en) 2010-10-12
WO2006074360A2 (en) 2006-07-13
EP1838867A2 (de) 2007-10-03
EP1838867A4 (de) 2009-03-04
US20080248500A1 (en) 2008-10-09
CA2593184A1 (en) 2006-07-13
JP2008527351A (ja) 2008-07-24
WO2006074360A3 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
Kuppusamy et al. Proteins are potent biomarkers to detect colon cancer progression
She et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Kwon et al. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
DE602007007209D1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
WO2007035766A3 (en) Biomarker for prostate cancer
Zergoun et al. IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients
ATE474228T1 (de) Reagenz für hämoglobinabbau
Yang et al. Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
NO20090174L (no) Genfamilie (LBFL313) assosiert med kreft i bukspyttkjertel
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties